Genentech’s Divarasib Outperforms Rivals in NSCLC Trial
Event summary
- Genentech’s divarasib demonstrated superior progression-free and overall survival in a Phase III head-to-head trial against approved KRAS G12C inhibitors sotorasib and adagrasib.
- The Krascendo 1 study enrolled 338 patients with previously treated KRAS G12C-mutant advanced or metastatic NSCLC.
- Divarasib received Breakthrough Therapy Designation from the FDA in 2022 and Orphan Drug Designation in 2026 for KRAS G12C NSCLC.
- Genentech is advancing a comprehensive Phase III clinical development program for divarasib, including combination therapies and adjuvant settings.
The big picture
Genentech’s positive Phase III results for divarasib position the drug as a potential new standard in KRAS G12C NSCLC treatment, challenging existing therapies like sotorasib and adagrasib. The success of divarasib underscores the growing importance of precision medicine in oncology, particularly for genetically defined tumor subtypes. With a comprehensive clinical development program underway, Genentech aims to expand divarasib’s reach across different disease settings and lines of therapy.
What we're watching
- Regulatory Pathway
- The pace at which Genentech submits data to health authorities and secures approval for divarasib.
- Market Penetration
- Whether divarasib can displace sotorasib and adagrasib as the new standard of care in KRAS G12C NSCLC.
- Clinical Development
- The outcomes of Genentech’s broader Phase III program, including combination therapies and adjuvant settings.
Related topics